声明：我长持此股。
产品：多类癌症早期血液筛查。基本上是独一分。早期实验结果很好，正在进行大规模临床试验。未来可期。现在估值1.2B，已经翻了2-3翻，涨到5-10B应该不是问题（我拍脑门得出的结论）。
适合长持，也适合短炒
短炒：波动很大，比如可以在退休账户中逢低买入5千到1万，现价35左右，50以下都是丢（脑门结论），然后加5块60天自动卖出。
好股推荐gral (Grail)
版主： 牛河梁
#4 Re: 好股推荐gral (Grail)
一滴血 测癌症的事 又忘了？ 真是 鱼脑子。。
h2o 写了： 2025年 5月 15日 10:31 声明：我长持此股。
产品：多类癌症早期血液筛查。基本上是独一分。早期实验结果很好，正在进行大规模临床试验。未来可期。现在估值1.2B，已经翻了2-3翻，涨到5-10B应该不是问题（我拍脑门得出的结论）。
适合长持，也适合短炒
短炒：波动很大，比如可以在退休账户中逢低买入5千到1万，现价35左右，50以下都是丢（脑门结论），然后加5块60天自动卖出。
#7 Re: 好股推荐gral (Grail)
查一下chatGPT再说不迟。
GRAIL, Inc. (NASDAQ: GRAL) is a biotechnology company based in Menlo Park, California, specializing in early cancer detection through blood-based screening technologies. Founded in 2015 as a subsidiary of Illumina, GRAIL was spun off in June 2024 following regulatory pressures in the U.S. and Europe. Illumina retains a 14.5% stake in the company
Axios
Financial Times
.
Business Overview
GRAIL's flagship product, Galleri, is a multi-cancer early detection (MCED) blood test designed to identify over 50 types of cancer, including many that currently lack routine screening methods. The test is priced at $949 and is currently available only in the U.S. As of mid-2024, GRAIL has delivered over 180,000 Galleri tests and established more than 100 commercial partnerships, including collaborations with Quest Diagnostics and TRICARE Health Insurance
Reuters
TipRanks
. The company is conducting large-scale clinical trials, including one in the UK, aiming for FDA approval by early 2026
Reuters
.
Financial Performance
GRAIL reported a revenue of $31.97 million in Q2 2024, with a significant net loss reflected in a GAAP EPS of -$51.06. The company holds approximately $850 million in cash reserves but faces a high annual cash burn rate of around $400 million, exceeding management's targets
TipRanks
.
Stock Analysis
As of April 15, 2025, GRAIL's stock price stands at $24.85, marking a 78.14% increase over the past year. However, analysts have set a 12-month price target of $20, indicating a potential downside of approximately 19.5% from the current price. The stock is characterized by high volatility, with an average weekly movement of 22.1%, surpassing the biotech industry average of 11.3%
StockAnalysis
Simply Wall St
.
Investment Considerations
Pros:
Strong growth in screening revenue, with a 39% year-over-year increase, demonstrating robust demand for GRAIL's services.
Strategic partnerships with major healthcare providers are expected to expand the company's market reach.
Cons:
High cash burn rate raises concerns about financial sustainability.
Regulatory and reimbursement risks associated with the commercialization of novel technologies like MCEDs.
Decline in development services revenue by 13% year-over-year, indicating a slowdown in that segment
TipRanks
.
Investors should weigh the potential of GRAIL's innovative cancer detection technologies against the financial and regulatory challenges the company faces.
GRAIL, Inc. (NASDAQ: GRAL) is a biotechnology company based in Menlo Park, California, specializing in early cancer detection through blood-based screening technologies. Founded in 2015 as a subsidiary of Illumina, GRAIL was spun off in June 2024 following regulatory pressures in the U.S. and Europe. Illumina retains a 14.5% stake in the company
Axios
Financial Times
.
Business Overview
GRAIL's flagship product, Galleri, is a multi-cancer early detection (MCED) blood test designed to identify over 50 types of cancer, including many that currently lack routine screening methods. The test is priced at $949 and is currently available only in the U.S. As of mid-2024, GRAIL has delivered over 180,000 Galleri tests and established more than 100 commercial partnerships, including collaborations with Quest Diagnostics and TRICARE Health Insurance
Reuters
TipRanks
. The company is conducting large-scale clinical trials, including one in the UK, aiming for FDA approval by early 2026
Reuters
.
Financial Performance
GRAIL reported a revenue of $31.97 million in Q2 2024, with a significant net loss reflected in a GAAP EPS of -$51.06. The company holds approximately $850 million in cash reserves but faces a high annual cash burn rate of around $400 million, exceeding management's targets
TipRanks
.
Stock Analysis
As of April 15, 2025, GRAIL's stock price stands at $24.85, marking a 78.14% increase over the past year. However, analysts have set a 12-month price target of $20, indicating a potential downside of approximately 19.5% from the current price. The stock is characterized by high volatility, with an average weekly movement of 22.1%, surpassing the biotech industry average of 11.3%
StockAnalysis
Simply Wall St
.
Investment Considerations
Pros:
Strong growth in screening revenue, with a 39% year-over-year increase, demonstrating robust demand for GRAIL's services.
Strategic partnerships with major healthcare providers are expected to expand the company's market reach.
Cons:
High cash burn rate raises concerns about financial sustainability.
Regulatory and reimbursement risks associated with the commercialization of novel technologies like MCEDs.
Decline in development services revenue by 13% year-over-year, indicating a slowdown in that segment
TipRanks
.
Investors should weigh the potential of GRAIL's innovative cancer detection technologies against the financial and regulatory challenges the company faces.
#8 Re: 好股推荐gral (Grail)
正在进行的大规模临床试验 chatGPT
GRAIL is actively conducting several large-scale clinical trials to evaluate the Galleri® multi-cancer early detection (MCED) blood test, which aims to identify over 50 types of cancer through a single blood draw. Here are the key ongoing studies:
NCBI
+13
GRAIL
+13
Financial Times
+13
Major Ongoing Clinical Trials for Galleri
1. PATHFINDER 2 (U.S.)
Objective: Assess the safety and performance of Galleri in individuals aged 50 and older who are eligible for guideline-recommended cancer screenings.
Enrollment: Over 35,000 participants across more than 30 healthcare institutions in North America.
Timeline: Enrollment began in December 2021; results from the first 25,000 participants are expected in the second half of 2025.
Biotech Insider
+5
GRAIL
+5
Stock Titan
+5
Stock Titan
+3
BioSpace
+3
GRAIL
+3
2. NHS-Galleri Trial (U.K.)
Objective: Evaluate Galleri's effectiveness in reducing late-stage cancer diagnoses when used alongside standard National Health Service (NHS) screenings.
Enrollment: Over 140,000 participants aged 50 to 77.
Timeline: Final study visits completed; results anticipated in 2026.
NCBI
+5
Fierce Biotech
+5
GRAIL
+5
Clinical Lab Products
+3
Stock Titan
+3
GRAIL
+3
3. REACH (Galleri-Medicare Study, U.S.)
Objective: Assess the real-world clinical impact of Galleri among Medicare beneficiaries, focusing on reducing stage IV cancer diagnoses and evaluating healthcare resource utilization.
Enrollment: Up to 50,000 Medicare beneficiaries, with an emphasis on including historically underrepresented populations.
Timeline: First participant enrolled in July 2024; study is ongoing.
GRAIL
+4
Grail Investors
+4
evidencebaseonline.com
+4
GRAIL
+1
Grail Investors
+1
4. REFLECTION Study (U.S. Veterans Affairs)
Objective: Understand the real-world experience of Galleri in routine clinical settings among U.S. veterans, including those with toxic exposures.
Findings: Initial results indicate cancer signal detection rates consistent with other populations tested with Galleri.
GRAIL
5. SUMMIT Study (U.K.)
Objective: Validate Galleri's performance, particularly in individuals at high risk for lung cancer.
Enrollment: Approximately 130,000 participants aged 55 to 77.
Timeline: Study commenced in April 2019 and is expected to conclude in August 2030.
NCBI
+1
Fierce Biotech
+1
These studies are integral to GRAIL's efforts to obtain FDA approval for Galleri and to integrate the test into broader cancer screening programs. The Galleri test is currently available in the U.S. by prescription but has not yet received FDA approval.
GRAIL
+10
GRAIL
+10
Grail Investors
+10
Health
If you're interested in participating in a clinical trial or learning more about Galleri, you can visit GRAIL's official website or consult with your healthcare provider for more information.
GRAIL is actively conducting several large-scale clinical trials to evaluate the Galleri® multi-cancer early detection (MCED) blood test, which aims to identify over 50 types of cancer through a single blood draw. Here are the key ongoing studies:
NCBI
+13
GRAIL
+13
Financial Times
+13
Major Ongoing Clinical Trials for Galleri1. PATHFINDER 2 (U.S.)
Objective: Assess the safety and performance of Galleri in individuals aged 50 and older who are eligible for guideline-recommended cancer screenings.
Enrollment: Over 35,000 participants across more than 30 healthcare institutions in North America.
Timeline: Enrollment began in December 2021; results from the first 25,000 participants are expected in the second half of 2025.
Biotech Insider
+5
GRAIL
+5
Stock Titan
+5
Stock Titan
+3
BioSpace
+3
GRAIL
+3
2. NHS-Galleri Trial (U.K.)
Objective: Evaluate Galleri's effectiveness in reducing late-stage cancer diagnoses when used alongside standard National Health Service (NHS) screenings.
Enrollment: Over 140,000 participants aged 50 to 77.
Timeline: Final study visits completed; results anticipated in 2026.
NCBI
+5
Fierce Biotech
+5
GRAIL
+5
Clinical Lab Products
+3
Stock Titan
+3
GRAIL
+3
3. REACH (Galleri-Medicare Study, U.S.)
Objective: Assess the real-world clinical impact of Galleri among Medicare beneficiaries, focusing on reducing stage IV cancer diagnoses and evaluating healthcare resource utilization.
Enrollment: Up to 50,000 Medicare beneficiaries, with an emphasis on including historically underrepresented populations.
Timeline: First participant enrolled in July 2024; study is ongoing.
GRAIL
+4
Grail Investors
+4
evidencebaseonline.com
+4
GRAIL
+1
Grail Investors
+1
4. REFLECTION Study (U.S. Veterans Affairs)
Objective: Understand the real-world experience of Galleri in routine clinical settings among U.S. veterans, including those with toxic exposures.
Findings: Initial results indicate cancer signal detection rates consistent with other populations tested with Galleri.
GRAIL
5. SUMMIT Study (U.K.)
Objective: Validate Galleri's performance, particularly in individuals at high risk for lung cancer.
Enrollment: Approximately 130,000 participants aged 55 to 77.
Timeline: Study commenced in April 2019 and is expected to conclude in August 2030.
NCBI
+1
Fierce Biotech
+1
These studies are integral to GRAIL's efforts to obtain FDA approval for Galleri and to integrate the test into broader cancer screening programs. The Galleri test is currently available in the U.S. by prescription but has not yet received FDA approval.
GRAIL
+10
GRAIL
+10
Grail Investors
+10
Health
If you're interested in participating in a clinical trial or learning more about Galleri, you can visit GRAIL's official website or consult with your healthcare provider for more information.
#13 Re: 好股推荐gral (Grail)
你们都跟着我投资加密货币吧，我介绍你们一个平台，你们可以转钱
Hard times create strong men. Strong men create good times. Good times create weak men. And, weak men create hard times.
#17 Re: 好股推荐gral (Grail)
Mark 一下
现在 $48, $1.71B
新闻
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
https://finance.yahoo.com/news/grail-an ... 00935.html
现在 $48, $1.71B
新闻
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
https://finance.yahoo.com/news/grail-an ... 00935.html
h2o 写了： 2025年 5月 15日 10:31 声明：我长持此股。
产品：多类癌症早期血液筛查。基本上是独一分。早期实验结果很好，正在进行大规模临床试验。未来可期。现在估值1.2B，已经翻了2-3翻，涨到5-10B应该不是问题（我拍脑门得出的结论）。
适合长持，也适合短炒
短炒：波动很大，比如可以在退休账户中逢低买入5千到1万，现价35左右，50以下都是丢（脑门结论），然后加5块60天自动卖出。
x1
